Effects of infectious disease consultation and antimicrobial stewardship program at a Japanese cancer center: An interrupted time-series analysis
Fig 3
Trends in the days of narrow-spectrum antibiotic (ampicillin, ampicillin–sulbactam, cefazolin, and cefmetazole) therapy per 100 patients, by month, during Phase 2 of the intervention period.
Each dot refers to the days of narrow-spectrum antibiotic therapy per 100 patients in each month, and the slope is based on linear regression in the two phases. The explanation of each phase is as follows: Phase 1 (antimicrobial notification by the infection control team from April 1, 2018, to March 31, 2020); Phase 2 (establishing an infectious disease [ID] consultation service and implementation of the Antimicrobial Stewardship Program [ASP] from April 1, 2020, to March 31, 2021). The trend in the monthly DOT of the four narrow-spectrum antibiotics increased (coefficient: 0.47; 95% confidence interval [CI]: 0.37 to 0.57, p<0.001), and its level increased (coefficient: 1.76; 95% CI: 1.00 to 2.53, p<0.001).